Julie Hambleton

Julie Hambleton currently works at Erasca, Inc., as Independent Director from 2021, Onc.ai, Inc., as Independent Director, and Gennao Bio, Inc., as Independent Director from 2021.
Dr. Hambleton also formerly worked at Arch Oncology, Inc., as President, Chief Executive Officer & Director from 2020 to 2021, Genentech, Inc., as Medical Director-Global Clinical Development from 2003 to 2010, Accent Therapeutics, Inc., as Director from 2020 to 2021, IGM Biosciences, Inc., as Independent Director from 2018 to 2025, Springworks Therapeutics, Inc., as Independent Director from 2020 to 2025, Bristol Myers Squibb Co., as Vice President & Head-US Medical from 2016 to 2017, Five Prime Therapeutics, Inc., as Chief Medical Officer & Executive Vice President from 2015 to 2016, The University of California, San Francisco, as Associate Professor from 1993 to 2003, Clovis Oncology, Inc., as Vice President-Clinical Development from 2010 to 2012, and IDEAYA Biosciences, Inc., as Chief Medical Officer, SVP & Head-Development from 2018 to 2020.
Dr. Hambleton received her undergraduate degree from Duke University and doctorate degree from Case Western Reserve University School of Medicine.